LEADERS FREE Japan presented at CVIT and e-poster at EuroPCR. [2017]
BioFreedom is launched in Japan. [2017]
LEADERS FREE II completed enrolment of 1,200 patients in September. [2017]
Primary endpoint of BioFreedom USA presented at AHA 2016, and CRT. [2017]
Launch of our first, cobalt chromium biodegradable polymer drug-eluting stent. [2016]
FDA approves LEADERS FREE II which began enrolment in the USA and Europe. [2016]
Several pre-specified subgroups of LEADERS FREE are presented and confirm that BioFreedom benefits all patient subgroups: Acute Coronary Syndrome (ACS) are Oral Anti Coagulant (OAC) are presented at EuroPCR and Elderly patients at ESC. [2016]
LEADERS FREE 2 year follow up is presented at TCT and confirms the long term benefit of BioFreedom over BMS in HBR patients with the absence of late catch-up. [2016]
One-year results from LEADERS FREE presented at TCT. 1-month only DAPT course both significantly safer and more effective than a bare metal stent in High Bleeding Risk (HBR) Patients. [2015]
Enrolment of Biosensors first trial in the USA “BioFreedom USA” was completed. [2015]
Enrolment of LEADERS FREE Japan was completed. [2015]
OCT findings from EGO BioFreedom™ were presented at EuroPCR. [2015]
RUDI FREE began enrolment. The first all comers registry for BioFreedom™ [2015]
Enrollment in LEADERS FREE complete: Patient population data presented at EuroPCR. [2014]
Chroma Cobalt-Chromium BMS launched at EuroPCR. [2014]
BioFreedom granted conditional IDE for US-based clinical trial. [2014]
4-year results from BioFreedom FIM study presented at TCT: comparable long-term safety and efficacy to DES demonstrated. [2014]
Launch of Chroma™ our first cobalt chromium bare metal stent. [2013]
e-BioMatrix registry data presented at EuroPCR: confirms safety of BioMatrix over 12 months in ‘real world’ patient population of 5,000. [2013]
BioMatrix NeoFlex gains CE Mark approval. [2013]
BioFreedom gains CE Mark approval. [2013]
First patient enrolled in LEADERS FREE, world’s first prospective, randomised double-blind trial employing only a one-month course of DAPT after implantation of active stent. [2012]
Final 5-year results from LEADERS presented at TCT: reduced risk of clinical events vs Cypher Select, associated with reduced risk of VLST. [2012]
Comfortable AMI results published in JAMA: BioMatrix shown to reduce cardiac events in acute MI patients more effectively than a BMS. [2012]
BioMatrix Flex chosen as stent used in GLOBAL LEADERS, largest ever randomised clinical trial involving DES: Aim to enrol 16,000 patients from all-comers population to assess benefits of new antiplatelet regimens. [2012]
LEADERS 4-yr data presented at TCT & published in Lancet; show improved long-term outcomes for BioMatrix Flex compared with durable polymer DES. [2011]
BioFreedom 2-year FIM results presented at TCT: show comparable safety and efficacy to DES. [2011]
Biosensors International acquires remaining 50% of joint venture in China, JW Medical Systems Ltd. [2011]
LEADERS 3-yr data presented at TCT. [2010]
Biosensors International launches BioMatrix Flex abluminal biodegradable polymer DES. [2010]
Biosensors International presents 9, 12 months and 24 months LEADERS results showing comparable safety and efficacy to industry leading drug-eluting stent at ESC and TCT congresses. Peer-reviewed article highlighting 9-month LEADERS results published in The Lancet. [2008]
Biosensors International receives CE Mark approval for its BioMatrix™ abluminal biodegradable polymer DES and launch across Europe. [2008]
Biosensors International launches PTCA catheters. [2000]
Biosensors Japan receives Japanese Ministry of Health, Labor and Welfare approval for its coronary bare metal S-Stent™. [2006]
Biosensors International makes First-In-Man implantation of its BioFreedom™ polymer-free drug-eluting stent. [2006]
Axxion™ drug-eluting stent receives CE Mark approval for commercialization in the European Union countries. [2005]
Biosensors International receives patent from U.S. Patent and Trademark Office covering the use of anti-restenotic, immunosuppressive drugs in combination with a biodegradable drug-release polymer coating on a stent. [2005]
Biosensors International enters into Asset Purchase and Licensing Agreement with Advanced Cardiovascular Systems, Inc., a subsidiary of Guidant Corporation to utilize Biosensors' biodegradable polymer technology and clinical data generated under the FUTURE I and FUTURE II clinical trials conducted by Biosensors. [2003]
Biosensors International enters into agreement with Terumo Corporation with respect to the manufacturing, supply and distribution of Biosensors’ DES technologies on an exclusive basis in Japan and on a non-exclusive basis elsewhere in the world outside of the U.S. [2003]
Biosensors International acquires Occam International B.V. [2001]
Biosensors International makes its first entry into the interventional cardiology products market with commercialization of its CE Marked S-Stent™ bare metal stent. [2000]
Biosensors International starts development of drug-eluting stents. [1999]
Start of in-house research and development. [1995]
Biosensors International Pte Ltd is founded by Yoh-Chie Lu as a contract manufacturing company for critical care products. [1989]
